Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCX0K3)

Drug Name

Cinacalcet Drug Info

Synonyms

Cinacalcet [INN]; AMG 073; AMG073; Cinacalcet (USAN); Mimpara (TN); Sensipar (TN); N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine

Indication

Disease Entry	ICD 11	Status	REF
Hyperparathyroidism	5A51	Approved	[1]
Kidney disease	GC2Z	Phase 3	[1]

Therapeutic Class

Calcimimetics

Cross-matching ID

PubChem CID: 156419
ChEBI ID: CHEBI:48390
CAS Number: CAS 226256-56-0
TTD Drug ID: DMCX0K3
INTEDE Drug ID: DR0326
ACDINA Drug ID: D00131

Molecule-Related Drug Atlas

Molecule Type:

DTT

DME

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Extracellular calcium-sensing receptor (CASR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etelcalcetide	DMHP9BL	Secondary hyperparathyroidism	5A51.1	Approved	[8]
Encaleret	DMQSPFS	Autosomal dominant hypocalcemia	5A50.0Y	Phase 3	[9]
ASP7991	DM3TN1A	Hyperparathyroidism	5A51	Phase 2	[10]
MK-5442	DMHTIGU	Osteoporosis	FB83.0	Phase 2	[11]
ATF-936	DMWGKHZ	Osteoporosis	FB83.0	Phase 1	[12]
AXT-914	DM7ZU3B	Osteoporosis	FB83.0	Phase 1	[13]
R-568	DM5NWPD	N. A.	N. A.	Discontinued in Phase 2	[14]
Ronacaleret	DM10ZJP	Osteoporosis	FB83.0	Discontinued in Phase 2	[15]
NPS-2143	DMQPXLF	Osteoporosis	FB83.0	Discontinued in Phase 2	[16]
NPS-2390	DMMRY0Z	Cerebrovascular ischaemia	8B1Z	Preclinical	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[19]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[20]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[22]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[23]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[24]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[25]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[19]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[26]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[27]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[28]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[29]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[30]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[31]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[32]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[24]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[33]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[34]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[35]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[36]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[37]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[38]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[22]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[26]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[39]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[40]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[41]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[42]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[43]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[44]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[45]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[46]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[47]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[48]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[49]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[50]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[51]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[52]
Methadone	DMTW6IU	Advanced cancer	2A00-2F9Z	Approved	[53]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Drug(s)

Drug(s) Affected By Parathyroid hormone (PTH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[54]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[55]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[56]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[57]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[58]
Phosphate	DMUXQG7	Constipation	DD91.1	Approved	[59]
Paricalcitol	DMYBV3G	Hyperparathyroidism	5A51	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[61]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[61]
Seocalcitol	DMKL9QO	Rickets	5B57	Phase 3	[62]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[63]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[64]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[65]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[66]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[66]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[67]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[68]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[69]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[70]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[66]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Extracellular calcium-sensing receptor (CASR)	TTBUYHA	CASR_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)^{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[3]
Cytochrome P450 2D6 (CYP2D6)^{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[3]
Cytochrome P450 1A2 (CYP1A2)^{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Gene/Protein Processing	[5]
Parathyroid hormone (PTH)	OTD721UF	PTHY_HUMAN	Gene/Protein Processing	[6]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[7]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3308).
2	Clinical pipeline report, company report or official report of Amgen (2009).
3	Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11.
4	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
5	Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
6	Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. Am J Kidney Dis. 2006 Nov;48(5):832-7. doi: 10.1053/j.ajkd.2006.07.019.
7	Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035616)
11	Antagonist for calcium-sensing receptor. JTT-305/MK-5442. Clin Calcium. 2011 Jan;21(1):89-93.
12	ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011 Aug;49(2):233-41.
13	AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. Bone. 2014 Jul;64:204-10.
14	Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther. 1999 Jan;65(1):40-9.
15	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
16	Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Abeta42 prompted by exogenous fibrillary or soluble Abeta25-35 in human cortical astrocytes and neurons-therapeutic relevance to Alzheimer's disease. Biochim Biophys Acta. 2013 Oct;1832(10):1634-52.
17	The Extracellular Calcium-Sensing Receptor (CASR) Regulates Gonadotropins-Induced Meiotic Maturation of Porcine Oocytes.Biol Reprod.2015 Dec;93(6):131.
18	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
19	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
20	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
21	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
22	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
23	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
24	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
25	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
26	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
27	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
28	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
29	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
30	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
31	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
32	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
33	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
34	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
35	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
36	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
37	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
38	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
39	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
40	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
41	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
42	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
43	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
44	Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
45	Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
46	Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
47	Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
48	Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
49	Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
50	Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
51	Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
52	Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
53	Expression, purification, and characterization of mouse CYP2d22. Drug Metab Dispos. 2006 Jul;34(7):1167-74.
54	Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron. 1994;67(1):48-53. doi: 10.1159/000187887.
55	Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One. 2010 Dec 13;5(12):e15235. doi: 10.1371/journal.pone.0015235.
56	Phenytoin induced vitamin D deficiency presenting as proximal muscle weakness. Indian Pediatr. 2010 Jul;47(7):624-5. doi: 10.1007/s13312-010-0121-3.
57	Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
58	Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013 May;169(1):167-78.
59	Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol. 2008 May;3(3):658-64. doi: 10.2215/CJN.04981107. Epub 2008 Feb 6.
60	Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003 Apr;63(4):1483-90. doi: 10.1046/j.1523-1755.2003.00878.x.
61	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
62	A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer. 1998 Jul;78(1):6-13. doi: 10.1038/bjc.1998.434.
63	Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
64	Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
65	Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
66	Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
67	Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
68	Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
69	Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
70	Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.